Type 2 diabetes and cardiovascular disease: What next?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 2, 2014, Pages 109-120

  Joseph, Joshua J ^a   Golden, Sherita Hill ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cardiovascular disease; neuroendocrine; risk factors; sleep disorders; stress; type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; INSULIN; MELATONIN; ORAL ANTIDIABETIC AGENT;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; EXERCISE; GLYCEMIC CONTROL; HEALTH CARE POLICY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW CALORY DIET; MENTAL STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP QUALITY; SMOKING; SOCIAL STATUS; SURGICAL TECHNIQUE;

ANTICHOLESTEREMIC AGENTS; ASPIRIN; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR; SIMVASTATIN; SLEEP DISORDERS; SOCIOECONOMIC FACTORS; STRESS, PSYCHOLOGICAL;

EID: 84896843454     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000044     Document Type: Review

References (127)

1. Taylor KS, Heneghan CJ, Farmer AJ, et al. All-cause and cardiovascular mortality in middle-Aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care 2013; 36:2366-2371
2. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234
3. American Diabetes Association. Standards of medical care in diabetes -2013. Diabetes Care 2012; 36:S11-S66
4. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585
5. Patel A, Collaborative Group ADVANCE, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370:829-840
6. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. J Am Med Assoc 2010; 304:61-68
7. McBrien K. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: Systematic review and meta-Analysis. Arch Intern Med 2012; 172:1296
8. Sundström J, Sheikhi R, O ' stgren CJ, et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: Cohort study of 34 009 primary care patients. J Hypertens 2013; 31:1603-1610
9. O'Connor PJ, Vazquez-Benitez G, Schmittdiel JA, et al. Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes. Diabetes Care 2012; 36:322-327
10. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-Analysis of randomised controlled trials. Lancet 2009; 373:1765-1772
11. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151:394-403
12. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-Analysis of randomised controlled trials. BMJ 2011; 343:d4169-d14169
13. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2012; 36:1304-1311
14. Turner RC, Holman RR, Stratton IM, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865
15. Selvin E, Bolen S, Yeh H-C, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008; 168:2070
16. DREAM Trial Investigators. Dagenais GR, Gerstein HC, Holman R, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31:1007-1014
17. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326
18. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327-1335
19. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319-328
20. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145-154
21. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368:1279-1290
22. Orlich MJ. Vegetarian dietary patterns and mortality in Adventist health study 2. JAMA Intern Med 2013; 173:1230
23. Romeo S, Maglio C, Burza MA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care 2012; 35:2613-2617
24. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567-1576
25. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013; 36:2175-2182
26. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577-1585
27. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012; 35:1420-1428
28. Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension and hyperlipidemia. J Am Med Assoc 2013; 309:2240-2249
29. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 2007; 49:1772-1780
30. Knopp RH. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin- Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006; 29:1478-1485
31. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebocontrolled trial. Lancet 2004; 364:685-696
32. Trialists CT. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: A meta-Analysis. Lancet 2008; 371:117-125
33. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet 2010; 375:735-742
34. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012; 380:565-571
35. Navarese EP, Buffon A, Andreotti F, et al. Meta-Analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013; 111:1123-1130
36. Zhou Y, Yuan Y, Cai R-R, et al. Statin therapy on glycaemic control in type 2 diabetes: A meta-Analysis. Expert Opin Pharmacother 2013; 14:1575-1584
37. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345:790-797
38. Narayan KMV, Boyle JP, Thompson TJ, et al. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care 2007; 30:1562-1566
39. Neeland IJ, Turer AT, Ayers MCR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. J Am Med Assoc 2012; 308:1150
40. Rabkin SW, Mathewson FA, Hsu P-H. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: The Manitoba Study. Am J Cardiol 1977; 39:452-458
41. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the FraminghamHeart Study. Circulation 1983; 67:968-977
42. Wilson PWF, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med 2002; 162:1867-1872
43. Despre s J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-887
44. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-846
45. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853
46. Lau DCW. Adipokines: Molecular links between obesity and atheroslcerosis. AJP Heart Circ Physiol 2005; 288:H2031-H2041
47. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109:III-39-III-43
48. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145-154
49. Sjostrom L, Narbro K, Sjoström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752
50. Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in swedish obese subjects. N Engl J Med 2012; 367:695-704
51. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-Term cardiovascular events. J Am Med Assoc 2012; 307:56-65
52. Maggard-Gibbons M,Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes. J Am Med Assoc 2013; 309:2250-2261
53. Stefater MA, Wilson-Perez HE, Chambers AP, et al. All bariatric surgeries are not created equal: Insights from mechanistic comparisons. Endocr Rev 2012; 33:595-622
54. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143:913-916; e7
55. Qin R, Chen T, Lou Q, Yu D. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: Meta-Analysis of observational prospective studies. Int J Cardiol 2013; 167:342-350
56. Al-Delaimy WK, Manson JE, Solomon CG, et al. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med 2002; 162:273-279
57. Clair C. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. J Am Med Assoc 2013; 309:1014
58. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. J Am Med Assoc 2008; 300:2134-2141
59. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840-A11840
60. Colwell JA, Cushman M, Inzucchi SE, et al. ADA/AHA/ACCF scientific statement. Circulation 2010; 121:2694-2701
61. De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-Analysis of randomised controlled trials. BMJ 2009; 339:b4531-b14531
62. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8:21
63. Jane M Armitage, BSc, MBBS, MRCP, FFPH, Clinical Trial Service Unit, University of Oxford. A study of cardiovascular events in diabetes [Internet]. http://clinicaltrials.gov/ct2/show/NCT00135226
64. Heffner JE. Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. Chest J 2012; 141:1414
65. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: The Sleep AHEAD study. Arch Intern Med 2009; 169:1619
66. Agusti A. Association between treated and untreated obstructive sleep apnea and risk of hypertension. J Am Med Assoc 2012; 307:2169
67. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea. J Am Coll Cardiol 2013; 62:569-576
68. Colten HR, Altevogt BM, Institute of Medicine (U.S.), Committee on Sleep Medicine and Research. Sleep disorders and sleep deprivation: An unmet public health problem [Internet]. Washington, DC: National Academies Press; 2006. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=nap 11617. [Accessed 11 October 2013]
69. Hamer M, Batty GD, Kivimaki M. Sleep loss due to worry and future risk of cardiovascular disease and all-cause mortality: The Scottish Health Survey. Eur J Prev Cardiol 2011; 19:1437-1443
70. Mosca M, Aggarwal B. Sleep duration, snoring habits, and cardiovascular disease risk factors in an ethnically diverse population. J Cardiovasc Nurs 2012; 27:263-269
71. Strine TW, Chapman DP. Associations of frequent sleep insufficiency with health-related quality of life and health behaviors. Sleep Med 2005; 6:23-27
72. Nakade M, Takeuchi H, Kurotani M, Harada T. Effects of meal habits and alcohol/cigarette consumption on morningness-eveningness preference and sleep habits by Japanese female students aged 18-29. J Physiol Anthropol 2009; 28:83-90
73. National Sleep Foundation. Sleep and exercise in America 2013 [Internet]. http://www.sleepfoundation.org. [Accessed 11 October 2013]
74. Haario P, Rahkonen O, Laaksonen M, et al. Bidirectional associations between insomnia symptoms and unhealthy behaviours: Insomnia symptoms and unhealthy behaviours. J Sleep Res 2013; 22:89-95
75. National Sleep Foundation. Sleep in America 2011 [Internet]. http:// www.sleepfoundation.org. [Accessed 11 October 2013]
76. Kingsbury JH, Buxton OM, Emmons KM, Redline S. Sleep and its relationship to racial and ethnic disparities in cardiovascular disease. Curr Cardiovasc Risk Reports 2013; 7:387-394
77. Stamatakis KA, Kaplan GA, Roberts RE. Short sleep duration across income, education, and race/ethnic groups: Population prevalence and growing disparities during 34 years of follow-up. Ann Epidemiol 2007; 17:948-955
78. Kaneita Y, Uchiyama M, Yoshiike N, Ohida T. Associations of usual sleep duration with serum lipid and lipoprotein levels. Sleep 2008; 31:645
79. Buxton OM, Pavlova M, Reid EW, et al. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes 2010; 59:2126-2133
80. Broussard JL, Ehrmann DA, Van Cauter E, et al. Impaired insulin signaling in human adipocytes after experimental sleep restriction: A randomized, crossover study. Ann Intern Med 2012; 157:549-557
81. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: A systematic review and meta-Analysis. Diabetes Care 2009; 33:414-420
82. Knutson KL, Ryden AM,Mander BA, Van Cauter E. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med 2006; 166:1768
83. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141:846-850
84. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care 2006; 29:657-661
85. Altman NG, Izci-Balserak B, Schopfer E, et al. Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes. Sleep Med 2012; 13:1261-1270
86. Tochikubo O, Ikeda A, Miyajima E, Ishii M. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension 1996; 27:1318-1324
87. Lusardi P, Zoppi A, Preti P, et al. Effects of insufficient sleep on blood pressure in hypertensive patients: A 24-h study. Am J Hypertens 1999; 12:63-68
88. Gangwisch JE, Feskanich D, Malaspina D, et al. Sleep Duration and risk for hypertension in women: Results from The Nurses' Health Study. Am J Hypertens 2013; 26:903-911
89. King CR, Knutson KL, Rathouz PJ, et al. Short sleep duration and incident coronary artery calcification. J Am Med Assoc 2008; 300:2859-2866
90. Eguchi K, Hoshide S, Ishikawa S, et al. Short sleep duration and type 2 diabetes enhance the risk of cardiovascular events in hypertensive patients. Diabetes Res Clin Pract 2012; 98:518-523
91. Shankar A, Syamala S, Kalidindi S. Insufficient rest or sleep and its relation to cardiovascular disease, diabetes and obesity in a national, multiethnic sample. PLoS One 2010; 5:e14189
92. Hoevenaar-Blom MP, Spijkerman AMW, Kromhout D, et al. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: The MORGEN Study. Sleep 2011; 34:1487-1492
93. Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, Verschuren WM. Sufficient sleep duration contributes to lower cardiovascular disease risk in addition to four traditional lifestyle factors: The MORGEN study. Eur J Prev Cardiol 2013; 0:1-9
94. Dayoub JC, Ortiz F, Lopez LC, et al. Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide: Melatonin improves atorvastatin effects. J Pineal Res 2011; 51:324-330
95. Yang Y, Duan W, Jin Z, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reper fusion injury. J Pineal Res 2013; 55:275-286
96. Tengattini S, Reiter RJ, Tan D-X, et al. Cardiovascular diseases: Protective effects of melatonin. J Pineal Res 2008; 44:16-25
97. Scheer FAJL, Van Montfrans GA, van Someren EJW, et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43:192-197
98. Bonnefond A, Clément N, Fawcett K, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44:297-301
99. McMullan CJ, Schernhammer ES, Rimm EB, et al. Melatonin secretion and the incidence of type 2 diabetes. J Am Med Assoc 2013; 309:1388-1396
100. Chatterji P, Joo H, Lahiri K. Racial/ethnic-And education-related disparities in the control of risk factors for cardiovascular disease among individuals with diabetes. Diabetes Care 2011; 35:305-312
101. Conway BN, May ME, Blot WJ. Mortality among low-income African Americans and whites with diabetes. Diabetes Care 2012; 35:2293-2299
102. McEwen LN, Karter AJ, Waitzfelder BE, et al. Predictors of mortality over 8 years in type 2 diabetic patients: Translating research into action for diabetes (TRIAD). Diabetes Care 2012; 35:1301-1309
103. Goldfarb-Rumyantzev AS, Rout P, Sandhu GS, et al. Social adaptability index predicts overall mortality in patients with diabetes. J Diabetes Complications 2012; 26:44-49
104. Gebreab SY, Diez-Roux AV, Hickson DA, et al. The contribution of stress to the social patterning of clinical and subclinical CVD risk factors in African Americans: The Jackson Heart Study. Soc Sci Med 2012; 75:1697-1707
105. Hickson DA, Roux AVD, Wyatt SB, et al. Socioeconomic position is positively associated with blood pressure dipping among African-American adults: The Jackson Heart Study. Am J Hypertens 2011; 24:1015-1021
106. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:937-952
107. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:953-962
108. Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals with diabetes: A meta-Analysis and systematic review. Gen Hosp Psychiatry 2013; 35:217-225
109. Carlson ED, Chamberlain RM. Allostatic load and health disparities: A theoretical orientation. Res Nurs Health 2005; 28:306-315
110. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm Behav 2003; 43:2-15
111. McEwen BS. Sex, stress and the hippocampus: Allostasis, allostatic load and the aging process. Neurobiol Aging 2002; 23:921-939
112. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5:374-381
113. Flier JS, Underhill LH, McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338:171-179
114. Seeman TE, Singer BH, Ryff CD, et al. Social relationships, gender, and allostatic load across two age cohorts. Psychosom Med 2002; 64:395-406
115. Mair CA, Cutchin MP, Kristen Peek M. Allostatic load in an environmental riskscape: The role of stressors and gender. Health Place 2011; 17:978-987
116. Anagnostis P, Athyros VG, Tziomalos K, et al. The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 2009; 94:2692-2701
117. Champaneri S, Xu X, Carnethon MR, et al. Diurnal salivary cortisol is associated with body mass index and waist circumference: The multiethnic study of atherosclerosis. Obesity 2013; 21:E56-E63
118. Champaneri S, Xu X, Carnethon MR, et al. Diurnal salivary cortisol and urinary catecholamines are associated with diabetes mellitus: The Multi-Ethnic Study of Atherosclerosis. Metabolism 2012; 61:986-995
119. Golden SH. A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Curr Diabetes Rev 2007; 3:252-259
120. Champaneri S, Wand GS, Malhotra SS, et al. Biological basis of depression in adults with diabetes. Curr Diab Rep 2010; 10:396-405
121. Lam YY, Mitchell AJ, Holmes AJ, et al. Role of the gut in visceral fat inflammation and metabolic disorders. Obesity 2011; 19:2113-2120
122. Tousoulis D, Kampoli A-M, Papageorgiou N, et al. Pathophysiology of atherosclerosis: The role of inflammation. Curr Pharm Des 2011; 17:4089-4110
123. Kampoli A-M, Tousoulis D, Briasoulis A, et al. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011; 17:4147-4158
124. Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: Findings from the National Health and Nutrition Examination Survey 1999-2008-: Cardiovascular risk factor control. J Diabetes 2011; 3:337-347
125. Wong ND, Patao C, Wong K, et al. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res 2013; 10:505-513
126. Saydah SH. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004; 291:335
127. Farkouh ME, Boden WE, Bittner V, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013; 61:1607-1615